Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until
determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then
enrollment into Phase 2a expansion cohorts will be initiated.